Dr. Peter Soukas, MD
Claim this profileThe Miriam Hospital
Studies Peripheral Artery Disease
Studies Peripheral Vascular Disease
9 reported clinical trials
11 drugs studied
Affiliated Hospitals
Clinical Trials Peter Soukas, MD is currently running
SELUTION SLR™
for Peripheral Arterial Disease
This trial tests a special balloon called SELUTION SLR™ DEB 014 for patients with severe leg artery blockages. The balloon helps open the artery and releases medicine to prevent it from getting blocked again.
Recruiting1 award N/A
Vascular Stent
for Deep Vein Thrombosis
This study is a prospective, non-randomized, multicenter, single-arm, clinical study to evaluate the performance, safety and efficacy of the GORE® VIAFORT Vascular Stent for treatment of symptomatic iliofemoral venous obstruction.
Recruiting1 award N/A16 criteria
More about Peter Soukas, MD
Clinical Trial Related5 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Peter Soukas, MD has experience with
- Plain (Uncoated) Balloon Angioplasty (PTA)
- Bare Temporary Spur Stent System
- The Tack Endovascular System
- MicroStent
- Standard PTA
- Duo Venous Stent System
Breakdown of trials Peter Soukas, MD has run
Peripheral Artery Disease
Peripheral Vascular Disease
Peripheral Arterial Disease
Critical Limb Ischemia
Ischemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Peter Soukas, MD specialize in?
Is Peter Soukas, MD currently recruiting for clinical trials?
Are there any treatments that Peter Soukas, MD has studied deeply?
What is the best way to schedule an appointment with Peter Soukas, MD?
What is the office address of Peter Soukas, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.